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Fig. S1
Cyclin E level in MCF10A parental (P) or cyclin E over expressing stable cell clones {MCF10A CyE (B10) and MCF10A CyE (C3) (a) measured at RNA level by QPCR using primers that span cyclin E and Flag sequence thus show the levels of transfected flag tagged cyclin E in breast cells. (b) measured by immunofluorescence (IF) by using cyclin E anLbody that picked up both the endogenous and transfected cyclin E levels.
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A. Table S1 : P values for pair wise comparisons of the three groups (Note that e = 0.5 means that the variance within different punches/ cores is equal to variance between paLents. An e much larger than 0.5 indicates that the biomarker is highly variable within a paLent and thus it can be anLcipated that a representaLve value for a paLent will be obtained with great difficulty. The results shown in table 1 indicate the heterogeneity of the biomarkers for most cohorts is not so extensive, which means that there are not many erroneous measurements involved in the study.
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